Trial · NCT04508621
Results by group14
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 14 of 14
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline to Week 14 in the Numerical Rating Scale (NRS) Weekly Average of Daily Self-reported Average Pain Severity Scores. | TNX-102 SL Tablet, 5.6 mg | -1.6 | 95% Confidence Interval -1.8 to -1.3 | score on a scale | |
| Change From Baseline to Week 14 in the Numerical Rating Scale (NRS) Weekly Average of Daily Self-reported Average Pain Severity Scores. | Placebo SL Tablet | -1.3 | 95% Confidence Interval -1.5 to -1.1 | score on a scale | |
| Number of Patients With a Patient's Global Impression of Change (PGIC) Rating of Very Much Improved or Much Improved | TNX-102 SL Tablet, 5.6 mg | 76 | Participants | ||
| Number of Patients With a Patient's Global Impression of Change (PGIC) Rating of Very Much Improved or Much Improved | Placebo SL Tablet | 56 | Participants | ||
| Change From Baseline to Week 14 in the Fibromyalgia Impact Questionnaire - Revised (FIQ-R) Symptoms Domain Score. | TNX-102 SL Tablet, 5.6 mg | -15.3 | 95% Confidence Interval -17.6 to -13.1 | score on a scale | |
| Change From Baseline to Week 14 in the Fibromyalgia Impact Questionnaire - Revised (FIQ-R) Symptoms Domain Score. | Placebo SL Tablet | -12.0 | 95% Confidence Interval -14.2 to -9.8 | score on a scale | |
| Change From Baseline to Week 14 in the FIQ-R Function Domain Score | TNX-102 SL Tablet, 5.6 mg | -8.8 | 95% Confidence Interval -10.9 to -6.7 | score on a scale | |
| Change From Baseline to Week 14 in the FIQ-R Function Domain Score | Placebo SL Tablet | -8.4 | 95% Confidence Interval -10.5 to -6.4 | score on a scale | |
| Change From Baseline to Week 14 in the Patient Reported Outcomes Measurement Information System (PROMIS) Score for Sleep Disturbance | TNX-102 SL Tablet, 5.6 mg | -7.4 | 95% Confidence Interval -8.6 to -6.2 | score on a scale | |
| Change From Baseline to Week 14 in the Patient Reported Outcomes Measurement Information System (PROMIS) Score for Sleep Disturbance | Placebo SL Tablet | -5.1 | 95% Confidence Interval -6.2 to -4.0 | score on a scale | |
| Change From Baseline to Week 14 in the PROMIS Score for Fatigue | TNX-102 SL Tablet, 5.6 mg | -6.6 | 95% Confidence Interval -7.7 to -5.5 | score on a scale | |
| Change From Baseline to Week 14 in the PROMIS Score for Fatigue | Placebo SL Tablet | -5.4 | 95% Confidence Interval -6.4 to -4.3 | score on a scale | |
| Change From Baseline to Week 14 in the Weekly Average of the Daily Diary Assessment of Sleep Quality | TNX-102 SL Tablet, 5.6 mg | -1.5 | 95% Confidence Interval -1.7 to -1.3 | score on a scale | |
| Change From Baseline to Week 14 in the Weekly Average of the Daily Diary Assessment of Sleep Quality | Placebo SL Tablet | -1.3 | 95% Confidence Interval -1.5 to -1.0 | score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04508621/results